DXCM DEXCOM INC — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$74.75

Period return

+0.83 (+1.12%)

Volume

3.4M

2026-07-21O $76.12 H $76.95 L $74.08 C $74.75MA5 $75.56MA20 $72.56MA60 $69.24MA120 $68.49

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 07. 29.Highin 8 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 29.LowBUY2 months ago
Citigroup: Buy
US analyst rating / recommendation change.
2026. 05. 19.LowBUY2 months ago
Canaccord Genuity: Buy
US analyst rating / recommendation change.
2026. 05. 19.LowBUY2 months ago
B of A Securities: Buy
US analyst rating / recommendation change.
2026. 05. 18.LowSELL2 months ago
Barclays: Underweight
US analyst rating / recommendation change.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.03%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.06%
2026. 05. 05.LowBUY3 months ago
Citigroup: Buy
US analyst rating / recommendation change.
2026. 05. 02.LowBUY3 months ago
Canaccord Genuity: Buy
US analyst rating / recommendation change.
2026. 05. 02.LowBUY3 months ago
TD Cowen: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $82.04 · 25 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Sector: Healthcare
Industry: Medical Devices
HQ: San Diego, CA, United States
Fiscal year end: —
Employees: 11,000
IPO date: —

View details →

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 07. 29.	After market close (AMC)	$0.61	—	—	$1.29B	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$0.27	—	—	$1.04B	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$1.04	—	—	$2.92B	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$0.71	—	—	$1.93B	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	1,217,607	$80.81M	0.13%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	1,082,913	$71.87M	0.11%	—	New position
3	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	1,114,948	$70.02M	0.06%	—	New position
4	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	257,298	$16.16M	0.03%	—	New position

DEXCOM INC덱스컴

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 29.	Citigroup	—	Maintain	Buy → Buy	—	Citigroup: Buy
2026. 05. 19.	Canaccord Genuity	—	Maintain	Buy → Buy	—	Canaccord Genuity: Buy
2026. 05. 19.	B of A Securities	—	Maintain	Buy → Buy	—	B of A Securities: Buy
2026. 05. 18.	Barclays	—	Maintain	Underweight → Underweight	—	Barclays: Underweight
2026. 05. 05.	Citigroup	—	Maintain	Buy → Buy	—	Citigroup: Buy
2026. 05. 02.	Canaccord Genuity	—	Maintain	Buy → Buy	—	Canaccord Genuity: Buy